Explore All Access
Check if your research matches the topics covered in Molecular Cancer Therapeutics?
- Degree of match
- Common matching concepts
- Additional journal recommendations
Molecular Cancer Therapeutics : Impact Factor & More
eISSN: 1538-8514pISSN: 1535-7163
Share this on:
Check your submission readiness
Find out how your manuscript stacks up against 24 technical compliance and 6 language quality checks.
Molecular Cancer Therapeutics Key Metrics
CiteScore 
10.2
H-Index
190
Impact Factor
5 - 10
SJR
Q1Oncology
SNIP
1.21
Topics Covered on Molecular Cancer Therapeutics
Cancer
Antigen
Mutant
Lung cancer
Extracellular matrix
Head and neck
Immunotherapy
Tyrosine kinase
Breast cancer
Camptothecin
Gemcitabine
Radiation
Glioblastoma
Oxidative stress
Cell cycle
Antitumor activity
DNA damage
Monoclonal antibody
Lymphoma
Homologous recombination
Molecular Cancer Therapeutics Journal Specifications
| Overview | |
| Publisher | AMER ASSOC CANCER RESEARCH |
| Language | English |
| Frequency | Monthly |
| General Details |
View less
Planning to publish in Molecular Cancer Therapeutics ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Molecular Cancer Therapeutics
A B7-H3–Targeted CD28 Bispecific Antibody Enhances the Activity of Anti–PD-1 and CD3 T-cell Engager Immunotherapies
- 6 Nov 2024
- Molecular Cancer Therapeutics
Retraction: Combining PARP-1 Inhibition and Radiation in Ewing Sarcoma Results in Lethal DNA Damage.
- 4 Nov 2024
- Molecular cancer therapeutics
Preclinical characterization of XB002, an anti-tissue factor antibody-drug conjugate for the treatment of solid tumors.
- 4 Nov 2024
- Molecular cancer therapeutics
Selected Articles from This Issue
- 4 Nov 2024
- Molecular Cancer Therapeutics
Correction: Phage Display-Derived Peptide-Based Dual-Modality Imaging Probe for Bladder Cancer Diagnosis and Resection Postinstillation: A Preclinical Study.
- 4 Nov 2024
- Molecular cancer therapeutics
Emerging Role of the p53 Pathway in Modulating Natural Killer Cell Mediated Immunity.
- 29 Oct 2024
- Molecular cancer therapeutics
A B7-H3–Targeted CD28 Bispecific Antibody Enhances the Activity of Anti–PD-1 and CD3 T-cell Engager Immunotherapies
- 6 Nov 2024
- Molecular Cancer Therapeutics
Retraction: Combining PARP-1 Inhibition and Radiation in Ewing Sarcoma Results in Lethal DNA Damage.
- 4 Nov 2024
- Molecular cancer therapeutics
Preclinical characterization of XB002, an anti-tissue factor antibody-drug conjugate for the treatment of solid tumors.
- 4 Nov 2024
- Molecular cancer therapeutics
Selected Articles from This Issue
- 4 Nov 2024
- Molecular Cancer Therapeutics
Correction: Phage Display-Derived Peptide-Based Dual-Modality Imaging Probe for Bladder Cancer Diagnosis and Resection Postinstillation: A Preclinical Study.
- 4 Nov 2024
- Molecular cancer therapeutics
Emerging Role of the p53 Pathway in Modulating Natural Killer Cell Mediated Immunity.
- 29 Oct 2024
- Molecular cancer therapeutics
Compare Similar Journals with Molecular Cancer Therapeutics
Select Journals to Compare with Molecular Cancer Therapeutics
Total journals - 10
You can select up to 3 Journals at a time
Cancer Research
Publisher: AMER ASSOC CANCER RESEARCH
Cancers
Publisher: MDPI
Clinical Cancer Research
Publisher: AMER ASSOC CANCER RESEARCH
Frontiers in Oncology
Publisher: FRONTIERS MEDIA SA
Journal of Clinical Oncology
Publisher: LIPPINCOTT WILLIAMS & WILKINS
Oncotarget
Publisher: Impact Journals
Annals of Oncology
Publisher: ELSEVIER
International Journal of Molecular Sciences
Publisher: MDPI
Scientific Reports
Publisher: NATURE PORTFOLIO
BMC Cancer
Publisher: BMC
0 Journals Selected to compare with
Molecular Cancer Therapeutics
Compare journals across 7 parameters SJR Ranking, Topics covered, Indexing Database, Publication Review Time, Publication Type, Article Processing Charges & Recently Published papers
SJR Ranking, Topics covered, Indexing Database, Publication Review Time, Publication Type, Article Processing Charges & Recently Published papers
Get detailed Journal comparison report on your email by signing up
FAQs on Molecular Cancer Therapeutics
How long has Molecular Cancer Therapeutics been actively publishing? 
Molecular Cancer Therapeutics has been in operation since 2002 till date.
What is the publishing frequency of Molecular Cancer Therapeutics?
Molecular Cancer Therapeutics published with a Monthly frequency.
How many articles did Molecular Cancer Therapeutics publish last year?
In 2023, Molecular Cancer Therapeutics publsihed 719 articles.
What is the eISSN & pISSN for Molecular Cancer Therapeutics?
For Molecular Cancer Therapeutics, eISSN is 1538-8514 and pISSN is 1535-7163.
What is Citescore for Molecular Cancer Therapeutics?
Citescore for Molecular Cancer Therapeutics is 10.2.
What is the H Index for Molecular Cancer Therapeutics ?
H Index for Molecular Cancer Therapeutics is 190.
What is SNIP score for Molecular Cancer Therapeutics?
SNIP score for Molecular Cancer Therapeutics is 1.21.
What is the SJR for Molecular Cancer Therapeutics?
SJR for Molecular Cancer Therapeutics is Q1.
Who is the publisher of Molecular Cancer Therapeutics?
AMER ASSOC CANCER RESEARCH is the publisher of Molecular Cancer Therapeutics.
